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Abstract: Cholesterol metabolism is crucial for cells and, in particular, its biosynthesis in the central
nervous system occurs in situ, and its deregulation involves morphological changes that cause
functional variations and trigger programmed cell death. The pathogenesis of rare diseases, such as
Mevalonate Kinase Deficiency or Smith–Lemli–Opitz Syndrome, arises due to enzymatic defects in
the cholesterol metabolic pathways, resulting in a shortage of downstream products. The most severe
clinical manifestations of these diseases appear as neurological defects. Expanding the knowledge of
this biological mechanism will be useful for identifying potential targets and preventing neuronal
damage. Several studies have demonstrated that deregulation of the cholesterol pathway induces
mitochondrial dysfunction as the result of respiratory chain damage. We set out to determine whether
mitochondrial damage may be prevented by using protective mitochondria-targeted compounds,
such as MitoQ, in a neuronal cell line treated with a statin to induce a biochemical block of the
cholesterol pathway. Evidence from the literature suggests that mitochondria play a crucial role in the
apoptotic mechanism secondary to blocking the cholesterol pathway. Our study shows that MitoQ,
administered as a preventive agent, could counteract the cell damage induced by statins in the early
stages, but its protective role fades over time.
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1. Introduction
The biosynthesis of cholesterol represents a fundamental pathway for the homeostasis of cells, as
witnessed by the heterogeneous spectrum of disorders arising from genetic deficiencies of enzymes
involved in this pathway, ranging from inflammatory disorders to complex neurodevelopmental
diseases [1–3].
In general, the pathogenic mechanism of these disorders involves the shortage of compounds
downstream of the enzymatic defect, rather than an accumulation of toxic molecules [2,4].
Indeed, although cholesterol is the end stage product of this pathway, several intermediate
compounds can also contribute to the regulation of crucial cellular functions [1]. Moreover, the
synthesis of these molecules is finely regulated in each cell type, and it is critical in the central nervous
system where almost all cholesterol supply depends on in situ biosynthesis [5].
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In particular, defective synthesis of cholesterol can affect the development of neural cells, and
this deficiency may help to explain the occurrence of neurological symptoms in disorders of the
cholesterol pathway [2], as Mevalonic Aciduria (MIM#610377) [6] and Smith–Lemli–Opitz Syndrome
(MIM#270400) [7].
To date, we know that a common consequence of distinct alterations of the cholesterol pathway is
represented by the triggering of programmed cell death, but the exact mechanisms underlying this
effect are unclear [8,9]. Extending our knowledge of this biological process will be useful to identify
potential cellular targets for medications aimed at preventing neuronal damage [10].
In previous studies, we demonstrated that blocking the cholesterol pathway in neuronal cells
induces dramatic morphological changes to mitochondria, and we hypothesised that mitochondria
play a major role in the induction of programmed cell death [8,11]. In order to mimic the blockade
of the mevalonate pathway to study its molecular mechanisms at the mitochondrial level, our group
developed a biochemical model applicable to several cell lines, including the neuronal one. This method
identifies statins (lovastatin or simvastatin) as blocking systems of the same metabolic pathway that
cause an increase in inflammatory markers [8].
Other authors recently proposed that mitochondrial damage by distinct causes may be prevented
by protective mitochondrial-targeted compounds, such as MitoQ, MitoTempo, and MitoVitE [12,13].
In particular, the MitoQ, a ubiquinone similar to Coenzyme Q10, intervenes at the mitochondrial
level limiting the effects of oxidative damage produced by free radicals released in the cellular
respiration process, reducing inflammation and increasing the neuronal energy of the affected cells.
Although its mechanism of action is not fully known, some studies have indicated that MitoQ
accumulates selectively in the mitochondria and not in the cells in general and is more effective as
an antioxidant.
In vivo studies have shown that MitoQ rapidly enters neuronal mitochondria, destroys free
radicals, reduces oxidative insults produced by high inflammation, and maintains or even increases
neuronal energy in the affected cells. In recent years, this product has been considered promising for
the treatment of neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease [13].
Based on these considerations, we investigated the potential of MitoQ in a neuronal cell line,
DAOY, treated with lovastatin, as previously described [8], to induce a biochemical block of the
cholesterol pathway. The experimental design allowed us to observe the functional and morphological
changes induced by biochemical manipulation (Figure 1).
Figure 1. Schematic picture of the experimental design. DAOY cells were seeded (−24 h) and the
pre-treatment of MitoQ was administered 1 h before lovastatin stimulation (0 h). Cell analyses were
conducted after 12 and 48 h.
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2. Results and Discussion
2.1. MitoQ Effect on the Impedance Profile
As shown by the representative impedance graph (Figure 2A), lovastatin (red line) induced a
cytotoxic effect on cultured cells, proven by a decrease in the cell index (CI), a parameter derived by
measuring cell status (Figure 2B) [14,15]. Pre-treatment with MitoQ, 1 h before lovastatin (green line),
reduced the adverse effects linked to statin treatment—its protective actions occurred in the first 12 h
after cell stimulation and tended to fade as time went by (Figure 2B). MitoQ alone (pink line) showed
a line course that was comparable to the one of the untreated condition (blue line).
Figure 2. Real-time, label-free impedance analysis. (A) Representative impedance graph that shows the
effect of lovastatin treatment and the potential protective actions of MitoQ added 1 h before the statins
(pink: MitoQ; blu untreated; green Mitoq + Lova; red Lova). (B,C) DAOY cells were pre-incubated
with MitoQ or N-acetylcysteine (Nac) and then stimulated with statins to evaluate the cell index at 12
(B) and 48 (C) h. Results are expressed as means and SDs in percentages (%), normalised to the control
condition (Untr). (n = 3, *** p < 0.0001 based on a one-way ANOVA, Bonferroni post-test).
Lovastatin induced a statistically significant difference in normalized CI values when compared
to untreated cells, both at 12 h and at 48 h (12 h: Untr: 100.1 ± 10.47 vs. Lova: 48.45 ± 5.92, p < 0.0001;
Lova: 48.45 ± 5.92 vs. MitoQ + Lova: 80.17 ± 12.11, p < 0.0001) (48 h: Untr: 100 ± 10.01 vs. Lova: 14.56
± 10.79, p < 0.0001).
Interestingly, the effect of MitoQ seems not to be limited to its global antioxidant action, since
treatment with another potent and widely recognized ROS scavenger, N-acetylcysteine (Nac), failed to
protect DAOY cells against cell death due to statins (Figure 2C) [16] (12 h: Nac + Lova: 46.67 ± 11.41
vs. Lova: 48.45 ± 5.92, ns; 48 h: Nac + Lova 12.83 ± 1.17 vs. Lova 14.56 ± 10.79, ns) (Figure 2B,C).
MitoQ and Nac, when administered alone, showed a trend similar to the untreated condition in
both timings (12 h: MitoQ: 117 ± 19.81; Nac: 99.33 ± 5.16; Untr: 100.1 ± 10.47; ns) (48 h: MitoQ: 105.1
± 13.48; Nac: 93.67 ± 12.53; Untr: 100 ± 10.01; ns) (Figure 2B,C).
The results obtained at 12 h show the protective and antioxidant effects of MitoQ very strongly, and
this evidence includes a decrease at 48 h after stimulation. The results obtained with N-acetylcysteine
highlight the specific effects of MitoQ that are able to prevent the modification induced by the block of
the mevalonate pathway.
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The observation through Xcelligence from MitoQ-preincubation to Lovastatin stimulation allowed
us to choose the two time points to represent the extremes of the morphological and functional
cellular changes of the effect of MitoQ for their optimal characterisation. The analyses carried out at
intermediate times confirmed the change in cell morphology/function or adhesion strength and did
not contribute to providing significant data.
2.2. Lovastatin Induced Lipid Accumulation
To establish the morphological modifications between 12 and 48 h after lovastatin treatment and
the potential effect of MitoQ, we performed a first qualitative analysis using Oil Red O staining for
lipids (Figure 3) [17,18].
Figure 3. Representative light micrograph of Oil Red O staining in the DAOY cells. Neuronal cells were
cultured for 12 h (upper panels) and 48 h (lower panels) with lovastatin, and with or without MitoQ.
(A,E: Untreated condition; B,F: Lovastatin treatment alone; C,G: Lovastatin treatment associated with
MitoQ; D,H MitoQ treatment alone). Scale bar 10 µm.
The untreated condition, regardless of the time of analysis, showed optimum confluency.
A compact cell monolayer, much more evident at the 48 h analysis, was observed—this condition did
not appear to be altered by the presence of MitoQ in the culture media (Figure 3A,D,E,H) [19].
At 12 h after the lovastatin treatment, it was possible to observe disaggregation of the cellular
layer and the formation of little clusters, signs of cellular distress, which was offset by the presence of
MitoQ (Figure 3B,C). The dramatic effect of the blocking of the cholesterol pathway was highlighted
48 h after the statin treatment and did not recover with the addition of MitoQ (Figure 3F,G).
The Oil Red O staining allowed the lipid droplets that developed in DAOY cells treated with
lovastatin to be highlighted (Figure 3) through an optical micrograph of neuronal culture stained with
Oil Red O staining which selectively stained lipid droplets in the cells in red colour.
The block of the mevalonate pathway promoted the accumulation of Oil Red O stained lipid
droplets in neuronal cells (Figure 3B,F). This effect was observed independently of the time of
incubation but, in terms of cell density, the lipid droplet formation was more easily identifiable
at 12 h compared to 48 h. (Figure 3B,F). At 12 h, MitoQ was able to counteract this lipid droplet
formation (Figure 3C), and its effect suggests that the physiological function of the mitochondria is
involved in the metabolism of cholesterol.
2.3. MitoQ Is Able to Reduce Programmed Cell Death Induced by Statin Treatment
The harmful effect of lovastatin on DAOY cells was confirmed with the programmed cell
death (PCD) analysis, assessed by the Annexin V-FITC (A+) Apoptosis Detection Kit. As expected,
statin-treated cells were characterised by a major percentage of Annexin V positive cells, mostly at 48 h
post-stimulation (Figure 4A: a vs. b; e vs. f) (12 h: Untr: 4.50 ± 0.68 vs. Lova: 8.207 ± 1.71, ** p < 0.001)
(Figure 4B) (48 h: Untr: 15.39 ± 10.86 vs. Lova: 65.96 ± 18.47, *** p < 0.0001) (Figure 4C). The
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administration of MitoQ reduced the percentage of death cells at 12 h post-stimulation [20] (Figure 4A:
c vs. b; g vs. f) (12 h: MitoQ + Lova: 5.78 ± 0.82 vs. Lova: 8.207 ± 1.71, * p < 0.05) (Figure 4B) (48 h:
MitoQ + Lova: 63.92 ± 10.37 vs. Lova: 65.96 ± 18.47; ns) (Figure 4C). The MitoQ alone did not perturb
cell viability, neither at 12 h, nor at 48 h.
Figure 4. Programmed cell death of Lova-treated DAOY cells in the presence of MitoQ.
(A) Representative cytofluorimetric dot-plots of Annexin propidium iodide staining in all experimental
conditions at 12 h (upper panel) and 48 h (lower panel). (B,C) The results (A/P) obtained as means ±
SDs of A+ cells of three independent tests at 12 h (B) and 48 h (C) (n = 3, ns: not significant; * p < 0.05;
** p < 0.001,*** p < 0.0001 based on a one-way ANOVA with Bonferroni post-test).
The results highlight that 12 h of MitoQ pre-incubation led to a statistically significant decrease in
PCD. This protective effect induced by MitoQ was gradually lost at 48 h after lovastatin stimulation.
MitoQ, indeed, was not able to protect PCD in the long term.
Thus, the potential protective role of MitoQ in counteracting programmed cell death induced by
statin was not so evident in later stages. The results of the analyses at intermediate times (24 and 36 h)
are reported in the Supplementary Data (Figure S1).
2.4. MitoQ Reduces Morphological Changes Correlated with Deregulation of the Mevalonate Pathway
To understand the role of mitochondria and other cellular districts involved in the block of the
cholesterol pathway, we needed to investigate the precise morphology modification and the potential
effect of MitoQ in preventing the autophagy mechanism. (Figure 5) [21,22].
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Figure 5. Morphological and functional changes associated with the cholesterol pathway block.
Representative electron micrographs of DAOY cells incubated with lovastatin in the presence or
absence of MitoQ, for 12 h (upper panel) and for 48 h (lower panel), showing the untreated condition
(A,E), lovastatin treatment alone (B,F), and associated with MitoQ (C,G) and MitoQ alone (D,H).
12 h; (A) mitochondria are mainly oval in shape, exhibit regular membranes and cristae (arrows).
(B) Mitochondrial cristae are not well defined (arrows). The cytoplasm shows vesicles that appear
like empty mitochondria (black arrowheads). RER cisternae arranged themselves in the three space
directions among mitochondria (red arrowheads). (C) Cell conditions improved much more compared
to the lovastatin treatment alone. Most mitochondria were normal in shape (arrows). (D) Ultrastructure
features are quite similar to untreated cells. Mitochondria are well-shaped, and the elongated shape
is the most represented in these cell cultures (arrows). 48 h: (E) Mitochondria exhibit regular shapes,
membranes and cristae (arrow). (F) Several very large vesicles are present in the cytoplasm (arrows).
Some mitochondria show damaged cristae and clear areas in the matrix (arrowheads). (G) Large
autophagic vesicles are evident (arrowheads). A mitochondrion is detectable inside a vesicle (arrow).
Cytoplasmic mitochondria are normally shaped (red arrow). (H) Ultrastructure features are quite
similar to untreated cells. Mitochondria are well-shaped. They appear a little more elongated compared
to untreated cells (arrows). Bars = 3 micron.
After 12 h, the cellular control condition was represented by cells whose plasma membranes
and inner membranes were intact. The organelles and nuclear envelope, indeed, exhibited a regular
shape, and the chromatin showed normal architecture. The structure of the mitochondria was oval
and/or elongated, mitochondrial cristae were well shaped, and the cisternae of the rough endoplasmic
reticulum (RER) and other organelles were regular (Figure 5A). The framework in the presence of MitoQ
was quite similar to the control cell culture. Elongated mitochondria were more frequently represented
than oval ones (Figure 5D). The lovastatin treatment modified the cellular morphology. Vesicles
were observed with degenerate membranes in the inner space (). Many cells showed light vesicles
surrounded by membranes that seemed to be empty mitochondria. Several RER membranes arranged
themselves in the three spacial directions among the mitochondria (Figure 5B). Most mitochondria
were slightly swollen with degenerated cristae in the central area corresponding to a clear space in the
mitochondrial matrix and well conserved at the periphery (Figure 5B). Some mitochondria exhibited
not well-defined cristae.
MitoQ is able to rescue this alteration, and the cells appear in much better conditions than
Lova-treated cells. Most mitochondria are normal (Figure 5C). Others are similar to those described in
LOVA-treated cells (see above), but they show a much lower damage. In this case, we can observe
small clear spaces in the mitochondrial matrix, corresponding to a low level of cristae degeneration
(Figure 5C).
The microscopy analysis at 48 h showed cells quite similar to the 12 h control cultures, as
the mitochondria exhibited regular morphology shapes, membranes and cristae (Figure 5E). The
same occurred with the treatment of MitoQ, where the cells and their structures were analogous to
the controls (Figure 5H). Only rare autophagy signs could be detected. A dramatic morphologic
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change was associated with lovastatin treatment after 48 h (Figure 5F)—many apoptotic and necrotic
cells were present. Most cells were deeply modified. The cytoplasm was enriched with enormous
vesicles surrounded by membranes containing scarce, unidentifiable material and organelles ascribable
to mitochondria (Figure 5F). Other small vesicles with degraded material were present. Some
mitochondria exhibited damaged cristae and inner empty areas; others appeared normal in structure
(Figure 5F). Rare RER cisternae were visible. The potential protective role of MitoQ was not able to
rescue the programmed cell death induced by statins. Rare apoptotic and necrotic cells were detectable.
Most cells showed remarkable signs of autophagy [23] at different stages, as follows: (1) endoplasmic
reticulum membranes surrounded mitochondria during the process of enclosing them into vesicles;
and (2) large vesicles containing particulate material and/or damaged mitochondria showed evidence
of the active autophagic process. Many normal mitochondria were present in the cytoplasm, and also
other organelles were in very good conditions (Figure 5G).
2.5. The Blocking of the Mevalonate Pathway Induces Mitochondrial Dysfunction
To investigate the mitochondrial damage triggered by the blockage of the metabolic pathway,
we analysed the mitochondrial membrane potential (∆ΨM), commonly acknowledged as a marker of
cellular health, by measuring Rhodamine 123 fluorescence (Rho) [24].
Lovastatin treatment increased mitochondrial dysfunction, as shown by a reduction inthe median
fluorescence intensity (MFI) of Rho [25]. MitoQ pre-treatment restored, even if not in a significant
manner, the MFI values on DAOY cells, only at the 12 h analysis (Figure 6A,B) [26].
Figure 6. Mean fluorescent intensity (MFI) of Rhodamine 123 of three independent experiments at 12 h
(A) and 48 h (B). Data are expressed as means and SDs (n = 3, ** p < 0.001 based on one-way ANOVA
with Bonferroni post-test).
The intermediate analyses of MFI at 24 and 36 h confirmed the progressive increase in
mitochondrial dysfunction and the inability of MitoQ to protect mitochondria (Supplementary Data,
Figure S2).
3. Materials and Methods
3.1. Reagents
If not differently specified, reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Lovastatin (Lova, Mevinolin from Aspergillus terreus) was dissolved in ethanol which did not
exceed 0.01% of the final concentration in each well.
MitoQ was kindly provided by MP Murphy (MRC Mitochondrial Biology Unit, Cambridge, UK)
and dissolved in ethanol. N-Acetyl-L-cysteine (Nac) was distilled in distilled water.
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3.2. Cell Culture
DAOY (human-derived desmoplastic cerebellar medulloblastoma cell line), obtained from ATCC
(ATCC® HTB-186™, Manassas, VA, USA), was cultured in EMEM (Eagle’s Minimum Essential
Medium) (Euroclone, Milan, Italy), supplemented with 10% foetal bovine serum (FBS, Euroclone),
2 mM glutamine and 1× solution of penicillin-streptomycin (Sigma-Aldrich). Twenty-four hours
after seeding, cells were stimulated with pre-treatment of MitoQ (200 nM) for 1 h and then with
Lova (10 µM). At the end of the incubation period, the supernatant was collected for the cytokine
assay, while cells were used for impedance measurement, microscopy analysis and pelleted for the
programmed cell death (PCD) or mean fluorescence intensity assay.
3.3. The xCELLigence System and Impedance Measurement
The effects of the Lova and MitoQ treatment were evaluated with the xCELLigence RTCA DP
Instrument (Roche, Monza, Italy), which records the increase in electrical impedance due to the
presence of adherent cells on the well bottom covered by microelectrodes. In real-time and without the
addition of a label, the number, the morphology and the viability of attached cells were displayed as
alterations in the impedance and converted into an adimensional parameter called the “cell index”
(CI). A decrease in CI after adding a pharmacological compound could be due to a detachment or to
the death of cultured cells. Briefly, for this analysis, 5 × 103 DAOY were seeded in a 16 well E-plate in
200 µL of complete medium, and cultured in 5% CO2 at 37 ◦C. The cells were stimulated with MitoQ
or NAC (10 mM) and after 1 h with Lova. The impedance was measured every 15 min; this experiment
was reproduced in triplicate. The change in impedance was calculated by dividing the desired value
by the value of the untreated condition.
3.4. Oil Red O Staining
A stock solution of 0.35% Oil Red O (BDH Chemicals, Poole, UK) in isopropanol was prepared,
filtered twice using a 0.22 µm filter and diluted in double-distilled H2O (ddH2O; 3:2) prior to use.
To detect cellular lipid accumulation, DAOY-treated cells were gently washed with PBS and fixed
using 4% paraformaldehyde for 1 h at room temperature (RT). Subsequently, the cells were washed
twice using ddH2O and stained with Oil Red O solution for 20 min at RT. To remove the background
staining, the cells were washed for 5 min with 60% isopropanol solution. Lipid droplet accumulation
was detected under a microscope.
3.5. Programmed Cell Death Assay
The programmed cell death (PCD) of DAOY was analysed by flow cytometry using Annexin
V (A) and propidium iodide (PI) staining. Cells were stained with FITC-conjugated Annexin V
and propidium iodide (Annexin V-FITC Apoptosis Detection Kit, Immunostep, Salamanca, Spain)
following the manufacturer’s indications. Briefly, 12 and 48 h after stimulation, cells were harvested
from the Petri dish with 0.5% trypsin-EDTA solution (Sigma Aldrich) and washed with PBS. Cells
were stained with A and PI for 15 min, then washed with customer binding buffer.
Fluorescence was acquired with a FACSCalibur cell analyser and CellQuest software (version
5.1.1, Becton Dickinson, Milan, Italy) and then analysed with FlowJo software (version 7.6, Treestar,
Inc., Ashland, OR, USA). Debris was excluded from the plot based on the scatter, while the apoptotic
(A+/PI−; A+/PI+) and necrotic (A−/PI+) cells were characterised by the fluorescence emitted.
3.6. Immunohistochemistry
Cell pellets were fixed with 2.5% glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA,
USA) in 0.1 cacodylate buffer, at pH 7.3, for 1 h at room temperature. They were rinsed twice for
10 min in 0.1 cacodylate buffer and postfixed with 1% osmium tetroxide in the same buffer for 1 h
at 4 ◦C [14]. Pellets were then dehydrated in ascending alcohols, treated with propylene oxide and
Int. J. Mol. Sci. 2018, 19, 1523 9 of 12
embedded in araldite (Electron Microscopy Sciences). Ultrathin sections of the samples were cut on a
Top Ultra 150 ultramicrotome (Pabish, Germany) and collected on 300-mesh copper grids (3.05 mm
diameter). The grids were stained with uranyl acetate and lead citrate and examined at 80 kV using a
Jeol JEM 100S transmission electron microscope.
3.7. Mean Fluorescence Intensity (MFI)
MFI was analysed by flow cytometry (Rhodamine 123, Sigma-Aldrich). Results are expressed
as the median fluorescent intensity (MFI) of Rhodamine 123 from 3 independent experiments.
Fluorescence was acquired with a FACSCalibur cell analyser and CellQuest software (version 5.1.1,
Becton Dickinson) and then analysed with FlowJo software (version 7.6, Treestar).
3.8. Data Analysis
All results are expressed as means and standard deviations (SDs). Statistical significance was
calculated using one-way or two-way analyses of variance (ANOVA), and Bonferroni post-test
corrections were applied in the case of multiple comparisons. Analyses were performed using
GraphPad Prism software (version 5.0) (Graph Pad Software, San Diego, CA, USA).
4. Conclusions
Our study focused on the fundamental roles of mitochondria-targeted drugs, such as MitoQ,
in cellular protection after blocking of the cholesterol pathway [24]. To date, the etiopathogenesis
of rare inborn diseases associated with the cholesterol pathway, as well as Mevalonic Aciduria or
Smith–Lemli–Opitz Syndrome, still needs to be deeply studied [27]. The causative genes and symptoms
associated with this disease are known but even though it is widely hypothesised, the role of the
mitochondria in this pathogenesis remains unclear [20,27]. Data from the literature strongly supports
mitochondrial involvement in inflammasome activation and all evidence from our study converges
to establish that the mitochondria play a crucial role in the apoptotic mechanism, secondary to the
blocking of the cholesterol pathway, and that the antioxidant MitoQ, administered as a preventive
agent, could counteract cell damage induced by statins in the early stages (12 h post lovastatin
stimulation). This protective role fades over time.
Recently, several studies have highlighted the potential protective effects of MitoQ in cardiac [28],
respiratory [29] and renal pathologies [30].
Different experimental designs have shared evidence that MitoQ improves mitochondrial
respiration so much that it is considered a promising drug that induces both autophagy and
mitochondria-selective mitophagy. However, the mechanism by which MitoQ operates is unclear
and is subject to controversial interpretation. Indeed, Sun C. et al. [31] claimed that MitoQ regulates
autophagy by inducing a pseudo-mitochondrial membrane potential. However, Lyamzaev K.G. et al.
contradicted this evidence. According to these authors, the decrease of mitochondrial membrane
potential activates the mitophagy and is related to oxidative phosphorylation, which, in itself,
represents an inducer of the mitochondrial autophagy process [32].
The results obtained show that the action of statins has effects on various cellular districts,
including the mitochondria involved in signal transduction. In particular, biochemical blocking
induces dramatic changes at the morphological and functional levels, such as the determination of
programmed cell death. Microscopy evidence showed that the main effect of the MitoQ is to guarantee
the morphologic conservation of the mitochondria and consequently, the protection of the cell itself.
The correct understanding of the mechanism by which MitoQ acts is undoubtedly a fundamental
step towards enhancing protective effects on the mitochondria. Indeed, the temporary effects of MitoQ
are not able to restore the cellular changes caused by the cholesterol pathway block, but further studies
should be oriented towards identifying molecules able to strengthen the protective effects of MitoQ.
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